Nifty
Sensex
:
:
12987.00
44259.74
128.60 (1.00%)
431.64 (0.98%)

Pharmaceuticals & Drugs - Global

Rating :
55/99  (View)

BSE: 500257 | NSE: LUPIN

899.55
5.00 (0.56%)
26-Nov-2020 | 4:02PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  897.00
  •  906.95
  •  893.30
  •  894.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2330965
  •  20968.20
  •  1122.30
  •  504.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 40,547.86
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,398.88
  • 0.67%
  • 3.19

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.91%
  • 0.59%
  • 9.78%
  • FII
  • DII
  • Others
  • 20.35%
  • 19.81%
  • 2.56%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.21
  • 3.38
  • 2.13

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.71
  • -7.66
  • -4.70

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.07
  • -23.79
  • -18.51

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.71
  • 23.65
  • 22.80

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.13
  • 3.83
  • 2.79

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.69
  • 14.88
  • 13.71

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
3,835
3,882
-1%
3,528
3,878
-9%
3,846
3,887
-1%
3,769
3,947
-5%
Expenses
3,254
3,242
0%
3,040
3,131
-3%
3,320
3,107
7%
3,340
3,266
2%
EBITDA
581
641
-9%
488
747
-35%
525
779
-33%
429
682
-37%
EBIDTM
15%
16%
14%
19%
14%
20%
11%
17%
Other Income
25
128
-80%
43
67
-35%
209
73
185%
94
40
133%
Interest
34
83
-59%
44
84
-48%
107
84
27%
89
78
13%
Depreciation
213
253
-16%
215
250
-14%
214
219
-2%
253
219
16%
PBT
360
-113
-
272
479
-43%
495
551
-10%
-108
82
-
Tax
147
70
111%
164
216
-24%
105
294
-64%
767
245
213%
PAT
213
-183
-
108
263
-59%
390
257
52%
-875
-163
-
PATM
6%
-5%
3%
7%
7%
7%
-23%
-4%
EPS
4.70
-4.03
-
2.39
5.81
-59%
8.61
5.67
52%
-19.30
-3.60
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
14,978
16,837
16,751
15,804
17,494
14,256
12,770
11,287
9,641
7,083
5,819
Net Sales Growth
-4%
1%
6%
-10%
23%
12%
13%
17%
36%
22%
 
Cost Of Goods Sold
8,673
4,963
4,437
4,734
4,661
4,010
3,806
3,486
3,222
2,365
2,061
Gross Profit
6,305
11,874
12,315
11,070
12,833
10,245
8,964
7,801
6,420
4,718
3,758
GP Margin
42%
71%
74%
70%
73%
72%
70%
69%
67%
67%
65%
Total Expenditure
12,954
14,362
14,082
12,657
13,001
10,570
9,150
8,284
7,371
5,638
4,641
Power & Fuel Cost
-
443
442
434
378
381
363
334
320
269
205
% Of Sales
-
3%
3%
3%
2%
3%
3%
3%
3%
4%
4%
Employee Cost
-
2,987
2,770
2,865
2,850
2,142
1,747
1,465
1,267
970
768
% Of Sales
-
18%
17%
18%
16%
15%
14%
13%
13%
14%
13%
Manufacturing Exp.
-
1,852
1,732
2,088
2,270
1,766
1,321
1,130
977
753
604
% Of Sales
-
11%
10%
13%
13%
12%
10%
10%
10%
11%
10%
General & Admin Exp.
-
2,799
3,303
1,220
1,306
1,196
807
811
692
471
325
% Of Sales
-
17%
20%
8%
7%
8%
6%
7%
7%
7%
6%
Selling & Distn. Exp.
-
1,080
1,207
1,151
1,253
870
835
775
710
648
547
% Of Sales
-
6%
7%
7%
7%
6%
7%
7%
7%
9%
9%
Miscellaneous Exp.
-
238
193
166
284
205
271
284
185
163
547
% Of Sales
-
1%
1%
1%
2%
1%
2%
3%
2%
2%
2%
EBITDA
2,024
2,474
2,669
3,148
4,493
3,685
3,620
3,003
2,270
1,445
1,178
EBITDA Margin
14%
15%
16%
20%
26%
26%
28%
27%
24%
20%
20%
Other Income
370
484
333
150
107
185
240
116
28
14
22
Interest
274
363
302
204
153
59
10
27
41
35
34
Depreciation
895
970
846
1,086
912
487
435
261
332
228
171
PBT
1,020
1,625
1,853
2,008
3,535
3,324
3,415
2,832
1,925
1,196
994
Tax
1,183
1,147
902
288
979
1,059
970
962
584
309
115
Tax Rate
116%
131%
60%
53%
28%
32%
28%
34%
30%
26%
12%
PAT
-163
-274
612
248
2,549
2,256
2,403
1,836
1,314
868
865
PAT before Minority Interest
-162
-274
612
255
2,556
2,265
2,444
1,870
1,340
888
879
Minority Interest
1
0
0
-7
-7
-9
-41
-33
-26
-20
-15
PAT Margin
-1%
-2%
4%
2%
15%
16%
19%
16%
14%
12%
15%
PAT Growth
-194%
-145%
147%
-90%
13%
-6%
31%
40%
51%
0%
 
EPS
-3.60
-6.04
13.50
5.47
56.25
49.78
53.03
40.52
29.00
19.14
19.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
12,537
13,742
13,577
13,498
11,163
8,874
6,932
5,204
4,013
3,281
Share Capital
91
90
90
90
90
90
90
90
89
89
Total Reserves
12,231
13,433
13,275
13,234
10,959
8,728
6,816
5,108
3,921
3,191
Non-Current Liabilities
3,003
7,296
6,876
6,447
6,032
426
507
573
730
534
Secured Loans
1
359
448
217
6
12
24
38
28
54
Unsecured Loans
1,793
6,283
5,976
5,431
5,368
89
127
209
405
245
Long Term Provisions
296
371
357
309
190
162
132
112
77
37
Current Liabilities
9,225
6,130
5,096
6,121
5,061
3,729
2,630
3,007
3,120
2,507
Trade Payables
2,412
2,498
2,575
2,589
1,989
1,956
1,594
1,543
1,379
993
Other Current Liabilities
3,124
1,280
1,517
658
1,001
830
288
381
377
201
Short Term Borrowings
2,493
1,580
452
2,304
1,745
369
402
727
1,047
791
Short Term Provisions
1,196
772
551
569
326
574
345
356
317
522
Total Liabilities
24,810
27,215
25,589
26,100
22,289
13,054
10,135
8,843
7,935
6,374
Net Block
7,938
11,087
10,362
11,033
8,717
4,368
3,356
3,000
2,750
2,057
Gross Block
14,160
15,732
13,860
12,395
9,212
6,645
5,284
4,684
4,192
2,964
Accumulated Depreciation
6,222
4,645
3,498
1,362
495
2,276
1,928
1,684
1,442
908
Non Current Assets
9,396
13,362
13,379
14,147
12,402
5,221
4,035
3,700
3,593
2,869
Capital Work in Progress
940
1,640
2,598
2,133
2,702
552
286
311
435
478
Non Current Investment
36
186
27
22
14
3
2
2
3
3
Long Term Loans & Adv.
410
403
383
951
960
274
373
387
397
314
Other Non Current Assets
73
47
9
8
8
0
0
0
0
5
Current Assets
15,413
13,854
12,210
11,953
9,887
7,832
6,100
5,143
4,342
3,504
Current Investments
2,338
2,110
235
2,114
2
1,656
176
0
0
0
Inventories
3,457
3,837
3,662
3,642
3,274
2,504
2,129
1,949
1,733
1,200
Sundry Debtors
5,446
5,150
5,192
4,307
4,549
2,657
2,464
2,187
1,780
1,256
Cash & Bank
2,454
987
1,408
698
822
481
798
435
402
420
Other Current Assets
1,718
777
621
533
1,241
535
533
572
427
628
Short Term Loans & Adv.
1,181
992
1,091
658
762
295
275
340
306
516
Net Current Assets
6,188
7,724
7,114
5,832
4,826
4,103
3,471
2,136
1,222
997
Total Assets
24,810
27,215
25,589
26,100
22,289
13,054
10,135
8,843
7,935
6,374

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,469
1,666
1,751
4,114
-382
2,733
2,004
1,251
560
798
PBT
877
1,517
547
3,543
3,329
3,415
2,832
1,925
1,196
994
Adjustment
1,574
1,588
2,782
1,215
585
357
410
420
259
207
Changes in Working Capital
-471
-500
-1,019
505
-3,126
-95
-466
-549
-581
-160
Cash after chg. in Working capital
1,980
2,605
2,310
5,262
788
3,677
2,776
1,795
874
1,042
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-511
-939
-558
-1,149
-1,170
-944
-772
-544
-314
-244
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
1,107
-3,282
470
-2,527
-6,962
-1,055
-859
-522
-741
-520
Net Fixed Assets
-481
-463
-1,394
-876
481
-416
-309
-325
-390
-558
Net Investments
-68
-2,026
1,551
-3,173
-297
-2,281
-476
-1
-6
43
Others
1,656
-794
313
1,522
-7,146
1,643
-74
-196
-345
-5
Cash from Financing Activity
-891
744
-1,492
433
5,836
-197
-857
-663
109
-163
Net Cash Inflow / Outflow
1,685
-872
729
2,019
-1,508
1,482
288
66
-72
116
Opening Cash & Equivalents
544
1,416
687
780
2,095
607
311
245
296
164
Closing Cash & Equivalent
2,229
544
1,416
2,799
780
2,108
607
311
245
296

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
272
299
296
295
245
196
154
116
90
74
ROA
-1%
2%
1%
11%
13%
21%
20%
16%
12%
15%
ROE
-2%
5%
2%
21%
23%
31%
31%
29%
24%
30%
ROCE
6%
8%
4%
19%
24%
40%
41%
33%
24%
25%
Fixed Asset Turnover
2.12
1.93
2.07
1.62
1.80
2.15
2.28
2.19
1.99
2.10
Receivable days
61
66
64
92
92
73
75
75
78
74
Inventory Days
42
48
49
72
74
66
65
69
75
68
Payable days
66
68
69
60
63
64
64
64
64
61
Cash Conversion Cycle
37
46
44
105
103
74
76
80
89
80
Total Debt/Equity
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
Interest Cover
3
6
4
24
57
349
107
48
35
30

News Update


  • Lupin launches Tacrolimus Capsules USP
    25th Nov 2020, 13:10 PM

    Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg (RLD: Prograf) had an annual sales of approximately $303 million in the U.S.

    Read More
  • Lupin in alliance with Concord gets USFDA approval for Tacrolimus Capsules USP
    12th Nov 2020, 15:17 PM

    Tacrolimus Capsules USP are indicated for the prophylaxis of organ rejection in adult and pediatric patients

    Read More
  • USFDA concludes inspection of Lupin’s Somerset facility
    9th Nov 2020, 09:53 AM

    The inspection at the Somerset, NJ facility closed with thirteen observations

    Read More
  • Lupin experiences information security incident
    6th Nov 2020, 12:46 PM

    Restoration of the impacted systems is a priority and is underway

    Read More
  • Lupin reports Rs 211 crore consolidated net profit in Q2
    5th Nov 2020, 11:26 AM

    Total consolidated income of the company marginally decreased by 3.75% at Rs 3859.96 crore for Q2FY21

    Read More
  • Lupin wins five ‘INDIASTAR 2020’ awards for Excellence in Packaging
    24th Oct 2020, 09:18 AM

    The award was conferred by the Indian Institute of Packaging

    Read More
  • Lupin gets approval for Dimethyl Fumarate Delayed-Release Capsules
    6th Oct 2020, 12:44 PM

    The product is expected to be launched shortly

    Read More
  • Lupin launches Lapatinib Tablets
    1st Oct 2020, 09:32 AM

    Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb Tablets, 250 mg, of Novartis Pharmaceutical Corporation

    Read More
  • Lupin launches Atorvastatin Calcium Tablets USP
    28th Sep 2020, 13:07 PM

    The product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin launches Divalproex Sodium ER Tablets
    22nd Sep 2020, 15:33 PM

    The product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin launches Leflunomide Tablets
    2nd Sep 2020, 15:59 PM

    The product would be manufactured at Lupin’s Pithampur Unit I facility in India

    Read More
  • Lupin, Mylan launch Nepexto in Germany
    26th Aug 2020, 15:12 PM

    Nepexto is approved for all therapeutic indications of the reference product Enbrel

    Read More
  • Lupin gets USFDA’s nod for Generic Albuterol Sulphate MDI
    25th Aug 2020, 09:50 AM

    The company’s generic Albuterol Sulphate MDI will be manufactured at its Indore facility in India

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.